By entering the second phase, Merck gains access to a new multi-million member library of small molecule drug candidates. In addition, this development triggers the payment of an undisclosed technology access fee to Nuevolution from Merck.
Alex Gouliaev, CEO of Nuevolution, said: “We are pleased with Merck’s decision to proceed with the collaboration into its second phase. We look forward to decoding the active structures arising from this proprietary library.”